Media

Upfront With Algernon Pharmaceuticals CEO
Pharma Developer Licenses Patent for Treating Neuroendocrine Cancers from US Ivy League College
Streetwise Live! – Algernon Pharmaceuticals CEO Christopher Moreau and Dr. David Nutt Discuss Phase 1 DMT Study For Stroke
Proactive Investors Interview – Algernon Pharmaceuticals Phase 2 Human Study of Ifenprodil for IPF and Chronic Cough is Now 70% Enrolled
Stockhouse – Algernon Pharmaceuticals Makes Major Headway Toward Clinical Trials for Treatment of Stroke
Proactive Investors Interview – Algernon Pharmaceuticals Launches Ifenprodil Pancreatic Cancer Clinical Research Program
Weekend Dispensary – Could the ‘spirit molecule’ be a treatment option for stroke?
Psychedelic Finance – Interview with Dr. Rick Strassman | DMT Stroke Program Consultant, Algernon Pharmaceuticals
Algernon Pharmaceutical’s DMT Clinical Research Program for Stroke Receives Positive FDA Feedback
PRMediaNow Algernon Pharmaceuticals Update with CEO Christopher Moreau
Proactive Interview regarding 50% enrollment into the IPF/Chronic Cough
Psychedelic Finance – Interview with Professor David Nutt | Algernon Pharmaceuticals DMT Stroke Consultant
Interview with Algernon Pharmaceuticals CEO Christopher J. Moreau About New DMT Stroke Program
Algernon Pharmaceuticals DMT Stroke Program Update and Recap with CEO Christopher Moreau
DMT Update and Recap Interview with CEO Christopher Moreau and Host Cyndi Edwards of PRmediaNow
Could the “Spirit Molecule” DMT Assist in Stroke Recovery? – Technology Network
Algernon CEO Christopher Moreau and Consultant Dr. David Nutt Discuss the DMT Stroke Program on BioPub Webcast Hosted by Dr. KSS MD, PhD
Algernon Pharmaceuticals Looks to Highly Regarded UK Company to Conduct Phase 1 DMT Stroke Study
Microdose PsyCap Conference: Investment Opportunities and New Companies in the Sector
Psychedelic Capital Virtual Investment Conference – Feb 2021 | Microdose
BNN Bloomberg – How Algernon Pharmaceuticals is aiming to use psychedelics to aid stroke recovery
Proactive – Algernon Pharmaceuticals considers adding lung scarring for additional endpoint in Ifenprodil study
IFL Science – Psychedelic Drug DMT To Be Trialed On Stroke Victims
Stroke victims to get hallucinogenic drug DMT to stave off worst effects of life-threatening condition in first-of-its-kind trial, scientists say
Metro UK – Stroke victims to be given psychedelic drug DMT in groundbreaking study
Algernon Pharmaceuticals Launches Research Program for Treatment of Stroke Using Psychedelic Drug DMT
DMT Stroke Research: Algernon Pharmaceuticals Moving to the Head of the Pack
Algernon Pharmaceuticals Targets Psychedelic Drug DMT for Stroke Program
StreetSmart Live! Interview with CEO, Christopher Moreau and CSO, Dr. Mark Williams
A Letter From Algernon Pharmaceuticals CEO Christopher Moreau
Algernon Pharmaceuticals CEO Christopher Moreau to present at Proactive’s One2One Virtual Investor Conference to be held December 8, 2020
Algernon Pharmaceuticals Update with CEO Christopher Moreau Hosted by Cyndi Edwards of PR Media Now – Facebook Live – December 1, 2020
CEO Christopher Moreau joined Steve Darling from Proactive to discuss how the company has enrolled the final patient in its multinational Phase 2b/3 human study
CEO Christopher Moreau discusses enrollment of its 154th patient in human study
Algernon Pharmaceuticals to provide interim data from Ifenprodil Phase 2b/3 human study
Proactive Investor – Interview with CEO Christopher Moreau regarding the approval from the Data and Safety Monitoring Board to continue the study
Share via
Copy link
Powered by Social Snap